Pat A. Cerundolo, Mark A. Haddad, Andrew B. Loewenstein, and Colin J. Zick have been promoted to partner at local offices of Foley Hoag LLP. Foley Hoag is a law firm with 250 lawyers in offices in such locations as Boston and Washington, D.C.
Chris Quinn has been appointed as executive vice president of North American
sales by New Balance Athletic Shoe Inc., a Boston firm known for athletic footwear and apparel. Quinn was most recently with Folgers Coffee as senior vice president of sales and chief customer officer.
Richard Walovitch has joined WorldCare Clinical LLC as chief medical officer. The Boston company is an imaging contract research organization that helps pharmaceutical, biotechnology, and medical device firm conduct clinical trials. Before joining WorldCare Clinical, Walovitch was the senior vice president of clinical research at Acusphere Inc.
Diana W. Sullivan has joined Cambria Consulting Inc., a talent and human resource management consulting firm in Boston. Before joining Cambria, Sullivan was a cofounder and head of Lee Hecht Harrison's Leadership Consulting practice.
Mark Bates, Kristina Kennedy, and Don Magri have joined Second Rotation, the Boston company behind Gazelle.com, a website where consumers can go to either sell unwanted electronics products or to recycle them. Bates is now Second Rotation's director of applications and is responsible for the development of customer facing applications, including applications for Gazelle.com. Prior to Second Rotation, he served as director of development for Andover-based Helium.com. Kennedy joins Second Rotation as senior manager of branding and communications. Previously, she was at Zipcar Inc. Magri joins Second Rotation as senior manager of finance and will be responsible for day-to-day finances and supporting overall operations. Magri most recently served as manager of finance at Go2Media.
Ted Hibben has joined Cequent Pharmaceuticals as chief business officer. The Cambridge company is focused on developing RNAi-based treatments to prevent and treat human disease. Hibben comes to Cequent from Coley Pharmaceutical Group, where he was most recently vice president of business development and alliance management and played a key role in the company's $233 million acquisition by Pfizer Inc. in 2008.
(By Chris Reidy, Globe staff)